Abstract
Perphenazine is a phenothiazine derivative, recommended as a tranquillizer (Ayd, 1957; O'Reilly et al., 1957; Goldman, 1958; Preisig and Landman, 1958) and as an anti-emetic (Scurr and Robbie, 1958). The structural formula is 1-(2-hydroxyethyl)-4-3-(2-chloro-10-phenothiazyl)-propyl-piperazine; it has also been called Fentazin and Trilafon. Its action is similar to chlorpromazine, but it is said to be 5 or 6 times as potent, the side-effects are less severe and the potentiating effect on barbiturates is minimal. Extra-pyramidal symptoms have occurred but no serious blood-disorders or jaundice have been reported. The recommended out-patient dosage is 6 to 16 mg. daily; doses of 24 to 64 mg. daily may be used with in-patients. Autonomic side-effects such as blurred vision and dry mouth are said not to occur below 40 mg. daily, hypotension not below 150 mg. daily. The purpose of this trial was to see if perphenazine improved the symptoms of out-patients with anxiety and depression, as compared with a placebo, and also to match it with a recognized and widely used sedative, sodium amylobarbitone, in order to note any difference in effect.
Publisher
Royal College of Psychiatrists
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Psychostimulants for depression;Cochrane Database of Systematic Reviews;2008-04-23
2. Thioridazine in Neurotic, Anxious, and Depressed Patients;Psychosomatics;1974-07
3. Drugs in Depression;Psychopharmacology in Family Practice;1973
4. Placebo Response;Psychopharmacology in Family Practice;1973
5. Part 2. Improvement criteria in drug trials with neurotic patients;Psychological Medicine;1972-02